What is VIGL's current stock price?

As of now, VIGL is trading at $7.89, with a daily change of +0.13%.

What are VIGL stock strengths?

VIGL strengths include Earnings are forecast to grow, Upgraded on attractively valued, .

What are the risks associated with VIGL stock?

VIGL Key risk is its High Risk Level, .

What is VIGL next earnings date?

VIGL next earnings report is yet to be scheduled.

What is VIGL's current stock rating?

VIGL's current stock rating is Buy.

Should I buy VIGL stock right now?

Based on the current rating of Buy, it is advisable to consider Buy as your next step with VIGL stock.

Is VIGL a Strong Buy right now?

VIGL's current stock rating is Buy, which indicates whether it is a Strong Buy, Buy, Hold, Sell, or Strong Sell.

What does a 'Strong Buy' rating mean for VIGL?

A 'Strong Buy' rating for VIGL indicates that analysts are highly confident in the stock's potential for future growth.

What does a 'Strong Sell' rating mean for VIGL?

A 'Strong Sell' rating for VIGL suggests that analysts anticipate the stock will decline significantly and may not be a good investment.

What factors influence VIGL's stock rating?

VIGL's stock rating is influenced by factors such as market trends, earnings reports, risk factors, and overall sentiment from analysts.

Vigil Neuroscience (VIGL) Stock Analysis and Insights

LOGIN

Market Overview Trending Stocks Stock Screener Trade Ideas

Top Rated Most Active Strong Potential Positive Momentum Earnings Calendar

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist

VIGL

Vigil Neuroscience

$7.89

+$0.01 | +0.13%

Create Alerts

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 7.95

MKT CAP

$ 368.24M

52W Low

$ 1.31

VOL

$ 1.21M

P/E Ratio

N/A

AVG VOL

$ 1.58M

RSI

90.16

TREND

Uptrend

Chart

$1.7 (+364.12%)

$2.5 (+215.60%)

$2.35 (+235.74%)

$4.33 (+82.22%)

1year

6month

3month

1month

VIGL Latest Headlines +

Sanofi to acquire Vigil Neuroscience in Alzheimers drug play.

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline

Wed May 21, 2025

$2.31 | -6.85%

Activity

Explore our VIGL Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored VIGL Stock Strategies
Effective Risk Management

FIND US ON

Receive our VIGL Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

Ideas

Earnings

VIGL

Vigil Neuroscience

Current Price

$7.89

+$0.01 | +0.13%

52W High

$ 7.95

MKT CAP

$ 368.24M

52W Low

$ 1.31

VOL

$ 1.21M

P/E Ratio

N/A

AVG VOL

$ 1.58M

RSI

90.16

TREND

Uptrend

Create Alerts

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

VIGL Stock Analysis for the Last 90 Days

Login to view Vigil Neuroscience (VIGL) recommendation from the last 90 days from financial news and social media.

Chart

$1.7 (+364.12%)

$2.5 (+215.60%)

$2.35 (+235.74%)

$4.33 (+82.22%)

1year

6month

3month

1month

VIGL Latest Headlines

Sanofi to acquire Vigil Neuroscience in Alzheimers drug play.

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimer'.s disease to the neurology pipeline Houman Ashrafian MD PhDHead of Research and Development SanofiThis acquisition is fully supporting Sanofi'.s strategic focus on neurology and on advancing science and leveraging our expertise in immunology

Wed May 21, 2025

$2.31 | -6.85%

Activity

Press Release: Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline. Sanofi to acquire Vigil Neuroscience Inc. adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline

Wed May 21, 2025

$2.31 | -6.85%

Activity

Discover VIGL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of VIGL. We're here to help you make informed investment decisions today.

FIND US ON

Receive our VIGL Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

VIGL Stock trends

VIGL Stock performance

VIGL Stock analysis

VIGL investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

Sign up for free and

continue analysing VIGL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

Sign up for free and

continue analysing VIGL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

VIGL Stock Analysis for the Last 90 Days

VIGL Risk Level

VIGL Analysts Opinion

VIGL Street Consensus

VIGL Performance Sentiment

Technical Price Levels

VIGL Financial Health

Explore our VIGL Stock insights

Receive our VIGL Daily Alerts

VIGL Stock Analysis for the Last 90 Days

VIGL Street Consensus

Technical Price Levels

Discover VIGL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of VIGL. We're here to help you make informed investment decisions today.

Receive our VIGL Daily Alerts

VIGL Runner Alarm